DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021PRNewsWire • 09/23/21
DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech SummitPRNewsWire • 09/15/21
DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment ConferencePRNewsWire • 09/07/21
DURECT Corporation (DRRX) CEO Jim Brown on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of ProgramsPRNewsWire • 07/29/21
DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29PRNewsWire • 07/22/21
DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual SummitPRNewsWire • 07/14/21
DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)PRNewsWire • 06/23/21
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)PRNewsWire • 06/09/21
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of ProgramsPRNewsWire • 05/04/21
DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4PRNewsWire • 04/27/21
DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/05/21
DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of ProgramsPRNewsWire • 03/04/21
DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common StockPRNewsWire • 02/04/21